Uso del antígeno prostático específico (PSA) para el cribado de cáncer de próstata en la población de 70 años o más de una zona de salud urbana, 2018-2020. Un estudio transversal(Pag.-e 101876)

  1. A. Urquijo-Moraza 1
  2. J. Guinea-Castañares 2
  3. J.M. Iturralde-Iriso 2
  1. 1 Universidad del País Vasco/Euskal Herriko Unibertsitatea UPV/EHU, Vizcaya, España
  2. 2 Centro de Salud La Habana-Cuba, Álava, España
Journal:
Semergen: revista española de medicina de familia

ISSN: 1138-3593

Year of publication: 2023

Issue: 1

Pages: 4-4

Type: Article

DOI: 10.1016/J.SEMERG.2022.101876 DIALNET GOOGLE SCHOLAR

More publications in: Semergen: revista española de medicina de familia

Abstract

Objectives To describe the epidemiology and estimate the cost of Prostate-Specific Antigen (PSA) screening tests to men ≥ 70 years old in an urban health zone. Methods A cross-sectional study was performed. We obtained every PSA test made in the health zone from 2018 to 2020, and classified them retrospectively as screening (PSAc) or not according to pre-established criteria, reviewing electronic health records. Testing rates were calculated by centres and clinical specialities. The standard population was provided by the city register of inhabitants (VM70). Cost estimation was made using our health system's price list. Results Two thousand and thirty six PSA, of 888 men ≥ 70 years old were obtained, and 350 met screening classification criteria. Six adenocarcinomas were diagnosed from those tests. We estimated 76.07 PSAc/1000 VM70-year from any centre, 1.45 tests for each screened individual, and 15.71% prevalence. The standard population was 1534 men (mean 2018-2020, SD 45.37). Patients who were screened (median age 75, SD 4.04) were younger than those not screened. We estimated a total screening test cost of 9,751 €. Conclusions The epidemiology and cost of PSA screening tests to men ≥ 70 years old are reported, both in primary health care and in the hospital. PSA screening tests are common practice amongst professionals attending elderly men in our health zone, mostly in primary care. The screening testing rate of men without prostate cancer is similar to that reported in the literature.

Bibliographic References

  • C.P. Wild, E. Weiderpass, B.W. Stewart World Cancer Report: Cancer Research for Cancer Prevention International Agency for Research on Cancer, Lyon, Francia (2020) Google Scholar
  • J. Galceran, A. Ameijide, M. Carulla, A. Mateos, J.R. Quirós, D. Rojas, et al. Cancer incidence in Spain, 2015 Clin Transl Oncol., 19 (2017), pp. 799-825 View PDF Your institution provides access to this article. CrossRefView in ScopusGoogle Scholar
  • C. Juliá-Romero, K. Rechi-Sierra, J.U. Juan-Escudero Nuevas recomendaciones en el screening de cáncer de próstata mediante PSA Semergen., 47 (2021), pp. 342-347 View PDFView articleView in ScopusGoogle Scholar
  • U. Paschen, S. Sturtz, D. Fleer, U. Lampert, N. Skoetz, P. Dahm Assessment of prostate-specific antigen screening: an evidence-based report by the German Institute for Quality and Efficiency in Health Care BJU Int., 129 (2021), pp. 280-289 Google Scholar
  • D. Ilic, M. Djulbegovic, J.H. Jung, E.C. Hwang, Q. Zhou, A. Cleves, et al. Prostate cancer screening with prostate-specific antigen (PSA) test: a systematic review and meta-analysis BMJ., 362 (2018), p. k3519 View PDF CrossRefView in ScopusGoogle Scholar
  • A. Jalón Monzón, M. Alvarez Múgica, M. Jalón Monzón, S. Escaf Barmadah Qué debe saber el médico de primaria sobre los nuevos marcadores en el cáncer de próstata Semergen., 44 (2018), pp. 430-438 View PDFView articleView in ScopusGoogle Scholar
  • M. Marzo-Castillejo, C. Vela-Vallespín, B. Bellas-Beceiro, C. Bartolomé-Moreno, Y. Ginés-Díaz, E. Melús-Palazón Grupos de Expertos de Cáncer del PAPPS. Recomendaciones de Prevención del Cáncer. Actualización PAPPS 2020 Aten Primaria., 52 (2020), pp. 44-69 View PDFView articleView in ScopusGoogle Scholar
  • N. Mottet, R.C.N. van den Bergh, E. Briers, T. Van den Broeck, M.G. Cumberbatch, M. De Santis, et al. EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer—2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent Eur Urol., 79 (2021), pp. 243-262 View PDFView articleView in ScopusGoogle Scholar
  • J. Panach-Navarrete, A. Carratalá-Calvo, L. Valls-González, Sales-Maicas MÁ, J.M. Martínez-Jabaloyas Uso del antígeno prostático específico (PSA) en un departamento de salud nacional Arch Esp Urol., 68 (2015), pp. 647-654 View in ScopusGoogle Scholar
  • C. Juliá Romero Adhesión a las guías clínicas para el screening del cáncer de próstata en Atención Primaria e identificación de áreas de mejora. Tesis doctoral Universitat de València (2021) Google Scholar
  • J. Panach-Navarrete, A. Gironés-Montagud, E. Sánchez-Cano, C. Doménech-Pérez, J.M. Martínez-Jabaloyas Uso del antígeno prostático específico en atención primaria (PSA) Semergen., 43 (2017), pp. 189-195 View PDFView articleView in ScopusGoogle Scholar
  • A. Páez, M. Luján, L. Llanes, I. Romero, M.A. de la Cal, E. Miravalles, et al. PSA-Use in a Spanish Industrial Area Eur Urol., 41 (2002), pp. 162-166 View PDFView articleView in ScopusGoogle Scholar
  • M. Oller Colom, S. Jiménez Navarrete, A. Hidalgo García, E. Calvo Rosa, M.M. Pérez Herrera, R.M. Castellanos Duarte, et al. Actitud del médico de atención primaria en la detección precoz del cáncer de próstata mediante el antígeno prostático específico Aten Primaria., 26 (2000), pp. 323-326 View PDFView articleView in ScopusGoogle Scholar
  • J. Cepeda Piorno, M. Rivas del Fresno, E. Fuente Martín, E. González García, V. Muruamendiaraz Fernández, E. Fernández Rodríguez Ventajas y riesgos de la utilización del antígeno prostático específico (PSA) en el área sanitaria V de Gijón (Asturias) Arch Esp Urol., 58 (2005), pp. 403-411 View PDF View in ScopusGoogle Scholar
  • G.J. Díaz Grávalos, S. Reinoso Hermida, M. Fernández Silva, F.J. Jorge Rodríguez, I. Casado Górriz Relación entre el uso del antígeno prostático específico y tratamiento de bloqueo androgénico: un estudio ecológico Rev Clínica Med Fam., 9 (2016), pp. 16-22 View in ScopusGoogle Scholar
  • J.-F. Morère, C. Touboul, C. Lhomel, M. Rouprêt Dépistage du cancer de la prostate en France: résultats des enquêtes EDIFICE Prog En Urol., 30 (2020), pp. 332-338 View PDFView articleView in ScopusGoogle Scholar
  • S. Zechmann, S.D. Gangi, V. Kaplan, R. Meier, T. Rosemann, F. Valeri, et al. Time trends in prostate cancer screening in Swiss primary care (2010 to 2017) – A retrospective study PLoS One., 14 (2019), p. e0217879 View PDF CrossRefView in ScopusGoogle Scholar
  • T. Pathirana, R. Sequeira, C. Del Mar, J.A. Dickinson, B.K. Armstrong, K.J.L. Bell, et al. Trends in Prostate Specific Antigen (PSA) testing and prostate cancer incidence and mortality in Australia: A critical analysis Cancer Epidemiol., 77 (2022), p. 102093 View PDFView articleView in ScopusGoogle Scholar
  • C. Jiang, S.A. Fedewa, Y. Wen, A. Jemal, X. Han Shared decision making and prostate-specific antigen based prostate cancer screening following the 2018 update of USPSTF screening guideline Prostate Cancer Prostatic Dis., 24 (2021), pp. 77-80 View PDF Your institution provides access to this article. CrossRefView in ScopusGoogle Scholar
  • J.P. Vandenbroucke, E. von Elm, D.G. Altman, P.C. Gøtzsche, C.D. Mulrow, S.J. Pocock, et al. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): Explanation and Elaboration PLoS Med., 4 (2007), p. e297 View PDF CrossRefGoogle Scholar
  • A.V. D’Amico, R. Whittington, S.B. Malkowicz, D. Schultz, K. Blank, G.A. Broderick, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer JAMA., 280 (1998), pp. 969-974 View PDF This article is free to access. View in ScopusGoogle Scholar
  • P. Abrams, L. Cardozo, M. Fall, D. Griffiths, P. Rosier, U. Ulmsten, et al. The standardisation of terminology of lower urinary tract function: Report from the standardisation sub-committee of the International Continence Society Neurourol Urodyn., 21 (2002), pp. 167-178 View in ScopusGoogle Scholar
  • R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria; 2022. Disponible en: https://www.R-project.org/. Google Scholar
  • J. Cohen Statistical power analysis for the behavioral sciences (2 nd ed.), L. Erlbaum Associates, Hillsdale, N.J. (1988) Google Scholar
  • M. Marzo Castillejo, P. Cierco Peguera, X. Bonfill Cosp Cribado del cáncer de próstata Aten Primaria., 28 (2001), pp. 468-471 View PDFView articleView in ScopusGoogle Scholar